Skip to main content
Erschienen in: International Journal of Hematology 2/2018

20.12.2017 | Case Report

Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1RUNX1T1 leukemia with t(8;12;21)

verfasst von: Akihiro Abe, Yukiya Yamamoto, Akira Katsumi, Akinao Okamoto, Masutaka Tokuda, Yoko Inaguma, Kiyoko Yamamoto, Masamitsu Yanada, Tadaharu Kanie, Akihiro Tomita, Yoshiki Akatsuka, Masataka Okamoto, Toshiki Kameyama, Akila Mayeda, Nobuhiko Emi

Erschienen in: International Journal of Hematology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Variant chromosomal translocations associated with t(8;21) are observed in 3–4% of acute myeloid leukemia (AML) cases with a RUNX1RUNX1T1 fusion gene. However, the molecular events that occur in variants of t(8;21) are not well characterized. In the present study, we report genetic features of a variant three-way translocation of t(8;12;21)(q22;p11;q22) in a patient with AML. In this patient, leukemia cells lacked azurophilic granules, which does not correspond with the classic features of t(8;21). RNA-seq analysis revealed that TM7SF3 at 12p11 was fused to VPS13B at 8q22 and VPS13B to RUNX1, in addition to RUNX1RUNX1T1. VPS13B was located near RUNX1T1 and both were localized at the same chromosomal bands. The reading frames of TM7SF3 and VPS13B did not match to those of VPS13B and RUNX1, respectively. Disruption of VPS13B causes Cohen syndrome, which presents intermittent neutropenia with a left-shifted granulopoiesis in the bone marrow. Disruption of VPS13B may thus cause the unusual features of RUNX1RUNX1T1 leukemia. Our case indicates that rearrangement of VPS13B may be additional genetic events in variant t(8;21).
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat de Cytogenetique Hematologique GF. Acute myelogenous leukemia with an 8;21 translocation. A report on 148 cases from the Groupe Francais de Cytogenetique Hematologique. Cancer Genet Cytogenet. 1990;44:169–79.CrossRef de Cytogenetique Hematologique GF. Acute myelogenous leukemia with an 8;21 translocation. A report on 148 cases from the Groupe Francais de Cytogenetique Hematologique. Cancer Genet Cytogenet. 1990;44:169–79.CrossRef
2.
Zurück zum Zitat Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.CrossRefPubMed Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.CrossRefPubMed
3.
Zurück zum Zitat Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:2322–33.PubMed Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:2322–33.PubMed
4.
Zurück zum Zitat Trujillo JM, Cork A, Ahearn MJ, Youness EL, McCredie KB. Hematologic and cytologic characterization of 8/21 translocation acute granulocytic leukemia. Blood. 1979;53:695–706.PubMed Trujillo JM, Cork A, Ahearn MJ, Youness EL, McCredie KB. Hematologic and cytologic characterization of 8/21 translocation acute granulocytic leukemia. Blood. 1979;53:695–706.PubMed
5.
Zurück zum Zitat Huang L, Abruzzo LV, Valbuena JR, Medeiros LJ, Lin P. Acute myeloid leukemia associated with variant t(8;21) detected by conventional cytogenetic and molecular studies: a report of four cases and review of the literature. Am J Clin Pathol. 2006;125:267–72.CrossRefPubMed Huang L, Abruzzo LV, Valbuena JR, Medeiros LJ, Lin P. Acute myeloid leukemia associated with variant t(8;21) detected by conventional cytogenetic and molecular studies: a report of four cases and review of the literature. Am J Clin Pathol. 2006;125:267–72.CrossRefPubMed
6.
Zurück zum Zitat Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature. 2009;458:97–101.CrossRefPubMedPubMedCentral Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature. 2009;458:97–101.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Weinberg OK, Seetharam M, Ren L, Seo K, Ma L, Merker JD, et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009;113:1906–8.CrossRefPubMed Weinberg OK, Seetharam M, Ren L, Seo K, Ma L, Merker JD, et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009;113:1906–8.CrossRefPubMed
8.
Zurück zum Zitat Miyawaki S. JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML). Int J Hematol. 2017;106:310–25.CrossRefPubMed Miyawaki S. JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML). Int J Hematol. 2017;106:310–25.CrossRefPubMed
10.
Zurück zum Zitat McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG, et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol. 2011;7:e1001138.CrossRefPubMedPubMedCentral McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG, et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol. 2011;7:e1001138.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Kozu T, Miyoshi H, Shimizu K, Maseki N, Kaneko Y, Asou H, et al. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood. 1993;82:1270–6.PubMed Kozu T, Miyoshi H, Shimizu K, Maseki N, Kaneko Y, Asou H, et al. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood. 1993;82:1270–6.PubMed
13.
Zurück zum Zitat Rege K, Swansbury GJ, Atra AA, Horton C, Min T, Dainton MG, et al. Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leuk Lymphoma. 2000;40:67–77.CrossRefPubMed Rege K, Swansbury GJ, Atra AA, Horton C, Min T, Dainton MG, et al. Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leuk Lymphoma. 2000;40:67–77.CrossRefPubMed
14.
Zurück zum Zitat Isaac R, Goldstein I, Furth N, Zilber N, Streim S, Boura-Halfon S, et al. TM7SF3, a novel p53-regulated homeostatic factor, attenuates cellular stress and the subsequent induction of the unfolded protein response. Cell Death Differ. 2017;24:132–43.CrossRefPubMed Isaac R, Goldstein I, Furth N, Zilber N, Streim S, Boura-Halfon S, et al. TM7SF3, a novel p53-regulated homeostatic factor, attenuates cellular stress and the subsequent induction of the unfolded protein response. Cell Death Differ. 2017;24:132–43.CrossRefPubMed
15.
Zurück zum Zitat Balikova I, Lehesjoki AE, de Ravel TJ, Thienpont B, Chandler KE, Clayton-Smith J, et al. Deletions in the VPS13B (COH1) gene as a cause of Cohen syndrome. Hum Mutat. 2009;30:E845–54.CrossRefPubMed Balikova I, Lehesjoki AE, de Ravel TJ, Thienpont B, Chandler KE, Clayton-Smith J, et al. Deletions in the VPS13B (COH1) gene as a cause of Cohen syndrome. Hum Mutat. 2009;30:E845–54.CrossRefPubMed
16.
Zurück zum Zitat Kivitie-Kallio S, Rajantie J, Juvonen E, Norio R. Granulocytopenia in Cohen syndrome. Br J Haematol. 1997;98:308–11.CrossRefPubMed Kivitie-Kallio S, Rajantie J, Juvonen E, Norio R. Granulocytopenia in Cohen syndrome. Br J Haematol. 1997;98:308–11.CrossRefPubMed
17.
Zurück zum Zitat Seifert W, Holder-Espinasse M, Spranger S, Hoeltzenbein M, Rossier E, Dollfus H, et al. Mutational spectrum of COH1 and clinical heterogeneity in Cohen syndrome. J Med Genet. 2006;43:e22.CrossRefPubMedPubMedCentral Seifert W, Holder-Espinasse M, Spranger S, Hoeltzenbein M, Rossier E, Dollfus H, et al. Mutational spectrum of COH1 and clinical heterogeneity in Cohen syndrome. J Med Genet. 2006;43:e22.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Gueneau L, Duplomb L, Sarda P, Hamel C, Aral B, Chehadeh SE, et al. Congenital neutropenia with retinopathy, a new phenotype without intellectual deficiency or obesity secondary to VPS13B mutations. Am J Med Genet A. 2014;164A:522–7.CrossRefPubMed Gueneau L, Duplomb L, Sarda P, Hamel C, Aral B, Chehadeh SE, et al. Congenital neutropenia with retinopathy, a new phenotype without intellectual deficiency or obesity secondary to VPS13B mutations. Am J Med Genet A. 2014;164A:522–7.CrossRefPubMed
19.
Zurück zum Zitat Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:5705–17.CrossRefPubMed Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:5705–17.CrossRefPubMed
20.
Zurück zum Zitat Peniket A, Wainscoat J, Side L, Daly S, Kusec R, Buck G, et al. Del (9q) AML: clinical and cytological characteristics and prognostic implications. Br J Haematol. 2005;129:210–20.CrossRefPubMed Peniket A, Wainscoat J, Side L, Daly S, Kusec R, Buck G, et al. Del (9q) AML: clinical and cytological characteristics and prognostic implications. Br J Haematol. 2005;129:210–20.CrossRefPubMed
21.
Zurück zum Zitat Schoch C, Haase D, Haferlach T, Gudat H, Buchner T, Freund M, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia. 1996;10:1288–95.PubMed Schoch C, Haase D, Haferlach T, Gudat H, Buchner T, Freund M, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia. 1996;10:1288–95.PubMed
Metadaten
Titel
Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1–RUNX1T1 leukemia with t(8;12;21)
verfasst von
Akihiro Abe
Yukiya Yamamoto
Akira Katsumi
Akinao Okamoto
Masutaka Tokuda
Yoko Inaguma
Kiyoko Yamamoto
Masamitsu Yanada
Tadaharu Kanie
Akihiro Tomita
Yoshiki Akatsuka
Masataka Okamoto
Toshiki Kameyama
Akila Mayeda
Nobuhiko Emi
Publikationsdatum
20.12.2017
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 2/2018
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-017-2387-x

Weitere Artikel der Ausgabe 2/2018

International Journal of Hematology 2/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.